Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifaximin Blunted Higher Levels of Endotoxin in Cirrhosis Patients: a Randomized, Double Blind, Short Term Interventional Trial

NCT06630572 is registered in ClinicalTrials.gov with University of Roma La Sapienza as lead sponsor.

NCT NCT06630572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06630572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifaximin Blunted Higher Levels of Endotoxin in Cirrhosis Patients: a Randomized, Double Blind, Short Term Interventional Trial
Lead sponsor
University of Roma La Sapienza
Phase
Phase 4
Overall status
Terminated
Start date
April 3, 2021
Completion date
August 1, 2024
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coagulation disorder, endotoxemia, liver cirrhosis, platelet disorder